Edoxaban Subgroup Analysis of East Asian Patients “Consistent” with Global Study Results: Researcher

Subgroup analysis results of East Asian populations from a global PIII study, ENGAGE AF-TIMI 48, which compared Daiichi Sankyo’s Lixiana (edoxaban) and warfarin in non-valvular atrial fibrillation (NVAF) patients, were consistent with the full results of the study, a researcher...read more